How to appeal a UnitedHealthcare myasthenia gravis & cidp denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for myasthenia gravis & cidp

Cited policy: OptumRx Vyvgart (efgartigimod alfa) IV / Vyvgart Hytrulo SC PA — FcRn Antagonist for gMG

Diagnosis of generalized MG (ICD-10 G70.0x) confirmed by neurologist. Anti-AChR-Ab+ documented by binding antibody titer. MG-ADL >=5 OR MGFA class II-IV. Inadequate response or intolerance to >=1 immunosuppressant (corticosteroid, azathioprine, mycophenolate, cyclosporine, tacrolimus, methotrexate) OR chronic IVIG/PLEX dependence. Reauthorization at 6 months with documented MG-ADL response.

How UnitedHealthcare denies myasthenia gravis & cidp — and how to counter it

Where UnitedHealthcare pushes back: 1) Must fail pyridostigmine + steroids + ≥1 IS sequentially before FcRn; 2) MG-ADL <5 considered insufficient; 3) AChR-Ab+ titer not documented; 4) Try chronic IVIG indefinitely first.

Counter-arguments that hold up: IST 2020 (Narayanaswami Neurology 2021) + AAN MG 2021 define refractory MG as inadequate response OR intolerance to ≥1 IS, OR chronic IVIG/PLEX dependence — NOT sequential failure of all classes. ADAPT (Howard Lancet Neurol 2021) — Vyvgart 67.7% MG-ADL responders vs 29.7% placebo, supported FDA approval Dec 17, 2021. Submit AChR-binding titer (>0.5 nmol/L). Cite individual MG-ADL bulbar/respiratory items if disabling. Document IS intolerance specifically (steroid-induced diabetes, mycophenolate cytopenia, azathioprine transaminitis with TPMT result).

What UnitedHealthcare typically denies for myasthenia gravis & cidp

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For myasthenia gravis & cidp, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the myasthenia gravis & cidp treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Soliris (MG)
• Ultomiris (MG)
• Vyvgart IV (MG)
• Vyvgart Hytrulo (MG)
• Rystiggo (MG)
• Zilbrysq (MG)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.